The Dry Eye Zone

Rebecca's Blog


Prolacria outlook still uncertain for the US

According to an August 12 investor conference call transcript, Inspire/Allergan have not made a final decision about whether to continue to pursue Prolacria (diquafosol) for the US market. It was recently approved in Japan where it is marketed as Diquas.